Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Get in touch with Dorota
Contact Dorota, search articles and posts on X, monitor coverage, and track replies from one place.
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
ArticleVolume 7, Issue 1102549Open access 1Center for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University, Stanford, CA, USA 2Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, University of Cologne, Medical Faculty and University Hospital Cologne, Cologne, Germany 3Cancer Center Cologne Essen (CCCE), Cologne, Germany 4Center for Molecular Medicine Cologne (CMMC), University of Cologne, Cologne, Germany 5University of Cologne,...
Correction to: Nature https://doi.org/10.1038/s41586-024-08171-9 Published online 13 November 2024 In the version of the article initially published, the reference Maude, S. L. et al. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N. Engl. J. Med. 378, 439–448 (2018) was originally ref. 2 and cited in the Abstract, but has now been removed from the Abstract and renumbered as ref.
Abstract H3K27M-mutant diffuse midline gliomas (DMGs) express high levels of the disialoganglioside GD2 (ref. 1). Chimeric antigen receptor-modified T cells targeting GD2 (GD2-CART) eradicated DMGs in preclinical models2. Arm A of Phase I trial no. NCT04196413 (ref. 3) administered one intravenous (IV) dose of autologous GD2-CART to patients with H3K27M-mutant pontine (DIPG) or spinal DMG (sDMG) at two dose levels (DL1, 1 × 106 kg−1; DL2, 3 × 106 kg−1) following lymphodepleting chemotherapy.
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
